Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data & AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma & Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2024 / Jul / Light Fantastic
Spectroscopy Clinical

Light Fantastic

Raman spectroscopy for esophagus cancer diagnosis

By Jessica Allerton 07/09/2024 2 min read

Share

Credit: RaPIDE Project

A new test for esophagus cancer diagnosis looks set to drastically reduce discovery time from a couple weeks to less than a minute.

Esophageal cancer, if caught early, is often treatable, potentially during the same diagnostic endoscopy. Rapid diagnosis, therefore, has the potential to revolutionize the field, which is what inspired Alex Dudgeon and colleagues in their latest study, RaPIDE (RAman Probe for In vivo Diagnostics (during oesophageal) Endoscopy) (1).

“Early on, we started treating patients with photodynamic therapy, which proved effective for those with early disease, but symptomatic patients were usually too far advanced to see a positive reaction,” says Dudgeon, “Knowing that innovative technology could have a big impact in this area, we set out to develop a technique to improve the identification of early disease.”

Credit: RaPIDE Project

The team faced a variety of challenges through the COVID-19 pandemic, including furlough and complications during regulatory approvals. However, with support from the University of Exeter, the University of Bristol, and Gloucestershire Hospitals NHS Foundation Trust, they proved triumphant in developing an endoscopic technique for early detection and diagnosis of esophageal cancer.

The technique uses Raman spectroscopy to measure the “fingerprint” of biological molecules present in the sample ahead of advanced statistical methods that help clinicians identify whether the area is cancerous.

Credit: RaPIDE Project

“Once proven, this technique would take away the need for tissue removal and could allow for treatment like RFA and EMR immediately – enabling real-time therapeutic targeting and monitoring of response,” Dudgeon explains.

As the system is tested in clinical trials to determine its effectiveness in living patients, the team strive to seeking funding for a larger multicenter trial – hoping to develop the diagnostic model for multiple pathologies, “We’re planning to explore the utilization of this technique in a range of organs – using the current probe for hollow organs, and a smart Raman needle probe for solid organs.”

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. ClinicalTrials.gov (2024). Available at: https://clinicaltrials.gov/study/NCT03468634.

About the Author(s)

Jessica Allerton

Associate Editor, The Analytical Scientist

More Articles by Jessica Allerton

False

Advertisement

Recommended

False

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.